Vaccines for Cancer

Mary Lenora Disis; Brie M. N. Chun; Kiranjit K. Dhillon; John B. Liao; Natasha B. Hunter; Denise L. Cecil

doi:10.1001/jama.2026.15540

Medicine & healthCancer care

Vaccines for Cancer

Mary Lenora Disis, Brie M. N. Chun, Kiranjit K. Dhillon, John B. Liao, Natasha B. Hunter, Denise L. Cecil

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result

Conclusions and Relevance: Cancer vaccines can treat several types of malignant neoplasms, including melanoma, prostate cancer, and bladder cancer.

Read the paper

Appeared: Wednesday, September 23. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.15540

Medicine & health Cancer care Sep 23, 2026
Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease
Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation.
S. Douglas, I. Kaaja, I. Ikonen and 13 more — medRxiv
Preprint
Medicine & health Cancer care Sep 23, 2026
Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1
A heavily pretreated germline BRCA1-mutant ovarian cancer patient achieved a confirmed partial response to RP-3467 plus olaparib (RECIST v1.1), with retrospective profiling revealing a TP53BP1 loss-of-function mutation previously linked to both PARPi resistance and POLQ dependency.
A. Sfeir, E. Rosen, M.-C. Mathieu and 29 more — medRxiv
PreprintReal-world use
Medicine & health Cancer care Sep 23, 2026
Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study
ConclusionsOne-day discharge after radical prostatectomy has increased over time and is now the predominant practice among Medicare beneficiaries, driven primarily by robotic surgery and treatment era.
J. Hanna, M. R. Shanahan, J. Sykes and 3 more — medRxiv
PreprintReal-world use
Medicine & health Cancer care Sep 23, 2026
Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
ResultsIn the RAS G12 population, daraxonrasib generated 0.652 additional life-years and 0.506 additional QALYs at an incremental cost of $253, 171, y i e l d in g an I C E R o f$ 500,637/QALY.
S. Han, N. Starasvetskaya, G. Terrero and 2 more — medRxiv
PreprintReal-world use
Medicine & health Cancer care Sep 23, 2026
Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma
ConclusionsEvo2-derived genomic representations improved clinicopathologic and transcriptomic prognostication across sarcoma cohorts and survival endpoints.
M. Esperanca-Martins, M. Sokolov Ravasqueira, S. Dias and 3 more — medRxiv
Preprint

All new papers on Cancer care

Vaccines for Cancer

In the authors' words

More on Cancer care that day

Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease

Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1

Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study

Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma

Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma